Hepatitis C In The News
Webinar Audio and Slide Presentation: Leveraging the IOM Report is now available
|
The Caring Ambassadors Program in partnership with the National Viral
Hepatitis Roundtable and Hepatitis C Advocates United is pleased
to announce our new Webinar series. Each month we will be hosting an interactive educational webinar
on viral hepatitis. We hope you will actively participate as we collectively augment
our knowledge base from experts in the field. |
Hepatitis C News
NVHR: Administration's 2011 Budget Proposal Shortchanges Five Million Americans Afflicted with Chronic Viral Hepatitis
WASHINGTON, Feb. 2 /PRNewswire–USNewswire/ — “Just weeks after the Institute of Medicine (IOM) blasted the federal government for its failure to respond to the nation's viral hepatitis epidemic, the Administration has continued a pattern of neglect with its 2011 budget proposal. In calling for an inadequate funding increase of $1.8 million for the Centers for Disease Control and Prevention's (CDC) Division of Viral Hepatitis, the Administration has shortchanged five million Americans afflicted with chronic viral hepatitis and has failed to translate the IOM's recommendations into decisive action, the National Viral Hepatitis Roundtable (NVHR) said today.”
Week Ending March 7, 2010
Scottish Government Launches Campaign on Hepatitis C
“People at risk of having the Hepatitis C virus are being encouraged to come forward for testing as part of a new Scottish Government campaign.”
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
“Abbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. Each antiviral agent will be dosed individually in combination with the current standard of care (SOC).”
Rock & Roll Antics Viral Film Warns Of 'Silent Disease'
“Rock ‘n’ roll antics of the rich and famous are being used to encourage those who might be at risk of hepatitis C to get tested and treated.”
Franken Urges End To Gay Blood Ban
“Sen. Al Franken is among 16 senators calling on the Food and Drug Administration (FDA) to end the ban on blood donations by gay men. In a letter to FDA commissioner Margaret Hamburg on Thursday, the senators called the policy “medically and scientifically unsound” and called out the double standard placed on gay men who want to be donors.”
Avail Clinical Research Announces Hepatitis C Research Studies in DeLand, FL
“Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, FL, announces the launch of several research studies to test investigational treatment options for those already diagnosed with hepatitis C.”
Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program
“Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.”
Hep C Sufferers Endangering Health To Get Treatment
B.C., Ont. won't cover antiviral drugs without liver damage, so patients binge drink
“Health-care workers who treat hepatitis C are raising the alarm about patients who are binge drinking and taking dangerous herbal concoctions to try to inflame their own livers in a desperate bid to get
provincial governments to pay for their medication.”
Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies
“Trial will evaluate safety and SVR rates with multiple 12-week response-guided regimens of telaprevir/VX-222-based combination therapy, including two-drug regimens of telaprevir and VX-222”
IL28B gene variation predicts response to hepatitis C treatment: will it change treatment of co-infection?
“Variations in the IL28B gene that have recently been linked to better treatment response among people with chronic hepatitis C virus (HCV) infection may also predict recovery in HIV/HCV-coinfected people, according to three studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) last week in San Francisco.”
For more Hepatitis C In The News, click here
Hep C Discussion Point™
The Caring Ambassadors Hepatitis C Program is pleased to announce the
launch of Hep C Discussion Point™ a question-and-answer survey
to help you manage your health while living with hepatitis C.
Hep C Discussion Point™ is a series of questions about your experience
living with and managing hepatitis C. You simply answer the questions,
and a customized list of information (discussion points) is produced
to help you and your health care providers work together to maximize
your health.
Hep C Discussion Point™ was designed by the Caring Ambassadors
Hepatitis C Program along with a team of medical advisors. Hep C Discussion
Point™ is an easy way to learn more about how best to work with
your doctors to improve or maintain your health while living with hepatitis
C.
After you’ve tried Hep C Discussion Point™, please provide
your suggestions
and comments by answering a few short questions.
The Caring Ambassadors Hepatitis C Program thanks the National
Hepatitis C Advocacy Council for funding support aiding in the
development of Hep C Discussion Point™.
Click here to enter
Hep C Discussion Point™.
| 
